11 results about "Anti-angiogenesis agent" patented technology

Methods for treating a cancer patient with a neutrophil-to-lymphocyte ratio (NLR) greater than 3 are disclosed, comprising administering a nonsteroidal glucocorticoid receptor antagonist (GRA) to such a cancer patient, effective to reduce the patient's NLR. The methods include administering a nonsteroidal GRA and a cancer treatment to such a cancer patient, effective to reduce the patient's NLR and enhance the treatment of the cancer patient. The GRA may be orally administered. The nonsteroidal GRA may be a nonsteroidal compound comprising a heteroaryl ketone fused azadecalin structure (e.g., relacorilant) or an octahydro fused azadecalin structure (e.g., exicorilant). The cancer treatment may include chemotherapy, immunotherapy, radiation therapy, administration of an anti-angiogenic agent, administration of a growth factor inhibitor, and surgery. The methods may enhance the cancer treatment, improve the prognosis of the cancer patient, improve the survival of the cancer patient, and provide beneficial clinical effects and advantages to the patient.

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administering to a metastatic colorectal cancer patient an effective amount of a PLK1 inhibitor (for example, onvansertib) and an effective amount of bevacizumab, wherein the patient has not received any treatment comprising bevacizumab within at least three months prior to the administration of the PLK1 inhibitor and bevacizumab in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

The present invention relates to the technical field of biomedicine, and particularly to a use of an OX40 activating antibody and an anti-angiogenic agent in the preparation of anti-tumor drugs. The OX40 activating antibody is OX86, and the anti-angiogenic agent is Verteporfin. OX40 induces an anti-tumor effect in T cells and induces a pro-tumor effect in endothelial cells. Therefore, the OX40 activating antibody and the anti-angiogenic agent are administered in combination, OX40 anti-tumor signaling is activated in the T cells, and the anti-angiogenic agent is used for blocking the pro-tumor effect of the OX40 activating antibody in the endothelial cells; and the two components act synergistically, showing a better anti-tumor effect compared to combination therapy of the OX40 activating antibody and a PD-1 monoclonal antibody CD279.

The present invention provides regimens and methods for treating cancer, including continuous infusion of coenzyme Q10. Coenzyme Q10 can be administered as a monotherapy or in combination with other agents, such as anti-cancer agents, chemotherapeutic agents, or anti-angiogenic agents. Coenzyme Q10 can be administered at two or more different rates.

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

To provide a combination with previously-proven cancer therapies such as anti-angiogenic agents in order to improve clinical response rates to anti-PD1 antibodies.SOLUTION: An antibody or an antigen-binding fragment thereof that binds specifically to both PD1 and VEGFR2, and a pharmaceutical composition comprising the same, are provided.SELECTED DRAWING: None

The present invention relates to the use of soluble CD27 as a biomarker to predict response to immune checkpoint inhibitor treatment. The inventors have collaborated with two queues of patients and have identified a soluble marker CD27 present in the plasma of renal cell carcinoma patients, the pre-treatment concentration of which can predict a response against PD-1 / PD-L1. The marker is more like a predictive marker of response to anti-PD-1 / PD-L1 therapy, rather than as a prognostic marker. In fact, it is independent of a better survival rate of metastatic renal cell carcinoma patients receiving treatment with anti-angiogenic agents. The markers are not associated with conventional clinical severity markers that classify metastatic kidney cancer patients.

The present disclosure relates to a mixture of antibodies of anti-CTLA4 and anti-PD1 or use of the mixture of antibodies in combination with a chemotherapeutic drug and / or an anti-angiogenic agent to treat hepatocellular carcinoma.

The anti-angiogenic agent or polypeptide has an amino acid segment substantially similar to domain 1 of CD2. The polypeptide has a beta fold formed by two segments. Methods of using such agents and polypeptides are also included. The agent or polypeptide has a terminal glycine.

Described herein is a chemoembolization therapy, which combines therapeutic effects of peripheral arterial occlusion with the local administration of an anti-cancer agent. A particle or microsphere occludes the arteries providing blood flow to the tumor, resulting in tumor oxygen deprivation. The anti-angiogenic agent is an anti-cancer drug, as described herein.